Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]MeS-IMPY
- Development stage
- Phase 1
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]MeS-IMPY is a radiolabeled small molecule used as a positron emission tomography (PET) imaging agent. It is chemically described as N,N-dimethyl-4-(6-(methylthio)imidazo[1,2-a]pyridin-2-yl)benzenamine with the methyl group labeled with carbon-11 ([11C]). The compound binds to beta amyloid plaques in the brain and is primarily developed for imaging amyloid deposition in Alzheimer's disease. Its mechanism of action involves selective binding to aggregated beta amyloid protein deposits, allowing visualization and quantification of amyloid burden via PET scans. The drug is synthesized by radiolabeling its precursor using [11C]-iodomethane produced from a cyclotron and formulated for intravenous injection as a sterile solution containing saline, polysorbate 80, and ethanol[1][2][3].
- Other names
- benzenamine n,n-dimethyl-4-(6-(methyl-11c-thio)imidazo(1,2-a)pyridin-2-yl)n,n-dimethyl-4-(6-(methylthio)imidazo[1,2-a]pyridin-2-yl)benzenamine
02
Targets
Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on [11C]MeS-IMPY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]MeS-IMPY.